Humacyte, Inc. (HUMA)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Humacyte, Inc. (HUMA) And Encourages Stockholders to Reach Out
NEW YORK CITY, NY / ACCESSWIRE / November 3, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Humacyte, Inc. ("Humacyte" or "the Company") (NASDAQ:HUMA). Investors who purchased Humacyte securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HUMA.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Humacyte, Inc. - HUMA
NEW YORK CITY, NY / ACCESSWIRE / November 1, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Humacyte, Inc. ("Humacyte" or the "Company") (NASDAQ:HUMA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Humacyte, Inc. (HUMA) And Encourages Stockholders to Connect
NEW YORK CITY, NY / ACCESSWIRE / November 1, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Humacyte, Inc. ("Humacyte" or "the Company") (NASDAQ:HUMA). Investors who purchased Humacyte securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HUMA.
Humacyte, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - HUMA
NEW YORK, NY / ACCESSWIRE / November 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Humacyte, Inc. ("Humacyte, Inc.") (NASDAQ:HUMA) concerning possible violations of federal securities laws. On October 17, 2024, the FDA revealed that it had identified several violations at Humacyte's North Carolina facility, including "no microbial quality assurance" and "no microbial testing," and "that quality oversight is inadequate.
Humacyte, Inc. (HUMA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESSWIRE / October 31, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Humacyte, Inc. ("Humacyte" or "the Company") (NASDAQ:HUMA). Investors who purchased Humacyte securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HUMA.
Humacyte, Inc. (HUMA) Declines More Than Market: Some Information for Investors
Humacyte, Inc. (HUMA) closed at $5.05 in the latest trading session, marking a -1.94% move from the prior day.
Levi & Korsinsky Reminds Humacyte, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - HUMA
NEW YORK, NY / ACCESSWIRE / October 30, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Humacyte, Inc. ("Humacyte, Inc.") (NASDAQ:HUMA) concerning possible violations of federal securities laws. On October 17, 2024, the FDA revealed that it had identified several violations at Humacyte's North Carolina facility, including "no microbial quality assurance" and "no microbial testing," and "that quality oversight is inadequate.
Humacyte Stock - Investors of Humacyte Encouraged to Contact Kehoe Law Firm, P.C. - HUMA
PHILADELPHIA, PA / ACCESSWIRE / October 30, 2024 / Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Humacyte, Inc. ("Humacyte" or the "Company") (NASDAQ: HUMA).
Lost Money on Humacyte, Inc.(HUMA)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
NEW YORK, NY / ACCESSWIRE / October 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Humacyte, Inc. ("Humacyte, Inc.") (NASDAQ:HUMA) concerning possible violations of federal securities laws. On October 17, 2024, the FDA revealed that it had identified several violations at Humacyte's North Carolina facility, including "no microbial quality assurance" and "no microbial testing," and "that quality oversight is inadequate.
Humacyte, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - HUMA
NEW YORK, NY / ACCESSWIRE / October 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Humacyte, Inc. ("Humacyte, Inc.") (NASDAQ:HUMA) concerning possible violations of federal securities laws. On October 17, 2024, the FDA revealed that it had identified several violations at Humacyte's North Carolina facility, including "no microbial quality assurance" and "no microbial testing," and "that quality oversight is inadequate.
Levi & Korsinsky Reminds Shareholders of an Investigation into Humacyte, Inc. (HUMA) Regarding Potential Securities Fraud Allegations
NEW YORK, NY / ACCESSWIRE / October 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Humacyte, Inc. ("Humacyte, Inc.") (NASDAQ:HUMA) concerning possible violations of federal securities laws. On October 17, 2024, the FDA revealed that it had identified several violations at Humacyte's North Carolina facility, including "no microbial quality assurance" and "no microbial testing," and "that quality oversight is inadequate.
Humacyte, Inc. (HUMA) Laps the Stock Market: Here's Why
In the most recent trading session, Humacyte, Inc. (HUMA) closed at $5.82, indicating a +1.75% shift from the previous trading day.
